Latest DrugPipeline News and Updates : DrugPipeline updates, DrugPipeline News , DrugPipeline around the world

Nishadil

Washington | 12°C (overcast clouds)

Regeneron's Bold Vision: Charting the Future of Healthcare at Bernstein Insights

Top story

Regeneron's Bold Vision: Charting the Future of Healthcare at Bernstein Insights

In focus

Latest feed

Roivant's Vision Unveiled: A Deep Dive into Their Promising Pipeline and Strategic Future

Merck's Bold Bet Beyond Keytruda: Forging a Future of Pharmaceutical Innovation

Merck's Master Plan: Building a Multi-Billion Dollar Future Beyond Keytruda

Teva's Strategic Pivot Gains Traction: Innovative Growth Offsets Generics Slide in Q2 2026

Latest headlines

Biontech's Post-Pandemic Trajectory: A Deep Dive into Pipeline Promises and Market Speculation

Biontech's Post-Pandemic Trajectory: A Deep Dive into Pipeline Promises and Market Speculation

AbbVie’s $11 Billion Bet on Oncology: Acquiring Apogee Therapeutics

AbbVie’s $11 Billion Bet on Oncology: Acquiring Apogee Therapeutics

AbbVie Takes the Leap: Why the $2.5 B Buy‑out of Apogee Therapeutics Could Redefine Immunology

AbbVie Takes the Leap: Why the $2.5 B Buy‑out of Apogee Therapeutics Could Redefine Immunology

AbbVie: A Reliable Anchor in Choppy Waters, But Is the Price Right for New Investors?

AbbVie: A Reliable Anchor in Choppy Waters, But Is the Price Right for New Investors?

Wockhardt Shares Rocket 16% After US FDA Gives Green Light to Zaynich

Wockhardt Shares Rocket 16% After US FDA Gives Green Light to Zaynich

Wockhardt Secures US FDA Approval for Zaynich, Shifts Gears from Lab Bench to Marketplace

Wockhardt Secures US FDA Approval for Zaynich, Shifts Gears from Lab Bench to Marketplace

The Eli Lilly Rollercoaster: Deciphering a Volatile Week in the Market

The Eli Lilly Rollercoaster: Deciphering a Volatile Week in the Market

Merck's Bold Bet: A Deep Dive into the Pipeline Powering Post-Keytruda Growth

Merck's Bold Bet: A Deep Dive into the Pipeline Powering Post-Keytruda Growth

Corcept Therapeutics: Has The Market Overreacted To The Bad News, Overlooking A Significant Upside?

Corcept Therapeutics: Has The Market Overreacted To The Bad News, Overlooking A Significant Upside?

Pfizer's Recent Rally: A Fleeting Illusion or Sustainable Recovery?

Pfizer's Recent Rally: A Fleeting Illusion or Sustainable Recovery?

Viking Therapeutics Rockets Skyward: Is Their Obesity Drug the Next Market Game-Changer?

Viking Therapeutics Rockets Skyward: Is Their Obesity Drug the Next Market Game-Changer?

Bristol Myers Squibb: Navigating the Patent Storm, Still a Cash Machine?

Bristol Myers Squibb: Navigating the Patent Storm, Still a Cash Machine?

Regeneron's Remarkable Resurgence: Charting the Course of a Biotech Comeback

Regeneron's Remarkable Resurgence: Charting the Course of a Biotech Comeback

Roche's Enduring Appeal: Navigating Growth Amidst Valuation Concerns

Roche's Enduring Appeal: Navigating Growth Amidst Valuation Concerns

Cramer's 2025 Check-Up: Is Merck Still a Buy?

Cramer's 2025 Check-Up: Is Merck Still a Buy?

Immunocore at the Crossroads: Steady Hands and the Search for Tomorrow's Breakthrough

Immunocore at the Crossroads: Steady Hands and the Search for Tomorrow's Breakthrough

The Curious Case of Catalyst Pharma: Cash-Rich, But What Comes Next?

The Curious Case of Catalyst Pharma: Cash-Rich, But What Comes Next?

J&J's Q3 Rollercoaster: Stock Dip, MedTech Hopes, and Tariff Tangles!

J&J's Q3 Rollercoaster: Stock Dip, MedTech Hopes, and Tariff Tangles!

Regeneron's Growth Horizon: Beyond the Core, Towards New Frontiers

Regeneron's Growth Horizon: Beyond the Core, Towards New Frontiers

Dianthus Unlocks Promising Future with Breakthrough Trial Results and Analyst Acclaim

Dianthus Unlocks Promising Future with Breakthrough Trial Results and Analyst Acclaim

Load more